What Is the Foundayo Pill?
Foundayo is orforglipron — Eli Lilly's once-daily oral small-molecule (non-peptide) GLP-1 receptor agonist tablet. FDA approved it on April 1, 2026 for chronic weight management in adults with obesity, or overweight plus at least one weight-related comorbid condition, used with a reduced-calorie diet and increased physical activity.
If you searched "foundayo," "foundayo pill," "orforglipron fda approval," or "orforglipron versus ozempic study," this is the consumer explainer. For the April approval news angle, see our earlier oral GLP-1 / Foundayo approval post. For titration detail as studied pre-label, see the orforglipron dosing guide.
This article is educational. It is not a prescription. Talk with a licensed clinician about any GLP-1.
Why an Oral Pill Matters
Classic GLP-1 medicines like injectable semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are peptides given under the skin. Peptides are hard to swallow as pills because stomach acid and enzymes break them down.
Orforglipron is different: it is a non-peptide small molecule that activates the GLP-1 receptor and can be taken by mouth. Per Lilly and the label, Foundayo is taken once daily with or without food — without the empty-stomach / limited-water ritual required for oral semaglutide (Rybelsus).
What FDA Approved (Label Snapshot)
From FDA's April 1, 2026 announcement and the Foundayo prescribing information:
| Topic | Label fact |
|---|---|
| Drug | Foundayo (orforglipron) tablets |
| Class | GLP-1 receptor agonist (oral) |
| Indication | Reduce excess body weight and maintain reduction long term in adults with obesity, or overweight with ≥1 weight-related comorbidity, plus diet and activity |
| How taken | Swallow whole, once daily, with or without food. Do not break, crush or chew. Max one tablet/day. |
| Approved strengths | 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg |
| Titration (label) | Start 0.8 mg; after ≥30 days → 2.5 mg; after ≥30 days → 5.5 mg; then may step to 9 → 14.5 → 17.2 mg after ≥30 days at each level based on response/tolerability. Max 17.2 mg once daily. |
| Not for | Use with another GLP-1 receptor agonist (not recommended). Safety/effectiveness in children not established. |
Boxed warning / key contraindications (label): risk language around thyroid C-cell tumors (class context); do not use with personal/family history of medullary thyroid carcinoma (MTC) or MEN 2, or known serious hypersensitivity to orforglipron.
Common adverse reactions (≥5%): nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, GERD, flatulence, hair loss. Serious warnings also cover pancreatitis, severe GI reactions, volume depletion/kidney injury, hypoglycemia (especially with insulin/secretagogues), hypersensitivity, diabetic retinopathy monitoring in T2D, gallbladder disease, and pulmonary aspiration risk with anesthesia/deep sedation.
ATTAIN-1: What Trials Studied (Not the Same as Every Label Strength)
Phase 3 ATTAIN-1 (NCT05869903), published in the New England Journal of Medicine, randomized 3,127 adults with obesity without diabetes to once-daily orforglipron 6 mg, 12 mg, or 36 mg vs placebo for 72 weeks (treatment-regimen estimand):
| Arm (as studied) | Mean weight change @ 72 weeks |
|---|---|
| 6 mg | −7.5% |
| 12 mg | −8.4% |
| 36 mg | −11.2% |
| Placebo | −2.1% |
At 36 mg, 54.6% lost ≥10%, 36.0% lost ≥15%, and 18.4% lost ≥20% of body weight (vs 12.9%, 5.9%, 2.8% on placebo). GI effects were the most common adverse events; discontinuation for adverse events was 5.3–10.3% on orforglipron vs 2.7% on placebo.
Important: trial maintenance doses (6 / 12 / 36 mg) are not identical to the commercial tablet ladder on the US label (0.8 → … → 17.2 mg max). Cite studied ranges as studied, and follow the prescribing information (and your clinician) for the approved product. Lilly's approval materials also highlight an efficacy-estimand figure of about 12.4% mean loss at the highest ATTAIN-1 dose among participants who stayed on treatment — a different estimand than the −11.2% treatment-regimen primary result above.
Foundayo / Orforglipron vs Injectable GLP-1s (Including Ozempic)
| Foundayo (orforglipron) | Injectable GLP-1s (e.g. semaglutide / tirzepatide) | |
|---|---|---|
| Molecule type | Small-molecule non-peptide | Peptide |
| Route | Daily oral tablet | Usually weekly subcutaneous |
| Food rules | Label: with or without food | N/A for injectables (Rybelsus oral semaglutide has strict fasting rules) |
| Regulatory status (US, 2026) | FDA-approved as Foundayo for weight management | Multiple approved brands (diabetes and/or weight) |
| Typical framing | Convenience / needle-free entry | Often higher mean weight-loss ceilings in their own pivotal programs |
"Orforglipron versus Ozempic" comparisons in media usually mix different trials, populations and estimands. Ozempic is injectable semaglutide approved for type 2 diabetes; Wegovy is the semaglutide brand for chronic weight management. Foundayo is a different molecule and route. Head-to-head conclusions need dedicated comparative studies — do not assume interchangeable results from separate programs.